Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Qiagen N.V. Common Shares (NY: QGEN )

38.90 -0.50 (-1.27%)
Official Closing Price Updated: 7:00 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,133,995
Open 39.12
Bid (Size) 38.38 (1)
Ask (Size) 39.47 (1)
Prev. Close 39.40
Today's Range 38.75 - 39.48
52wk Range 37.63 - 47.93
Shares Outstanding 227,985,334
Dividend Yield 3.39%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
QIAGEN receives U.S. clearance for second QIAstat-Dx mini gastrointestinal panel, expanding U.S. syndromic testing portfolio
From QIAGEN N.V.
Via Business Wire
QIAGEN takes legal action to defend QuantiFERON intellectual property and protect innovations in latent tuberculosis testing
From QIAGEN N.V.
Via Business Wire

Performance

YTD
-12.62%
-12.62%
1 Month
-2.94%
-2.94%
3 Month
-15.73%
-15.73%
6 Month
-15.14%
-15.14%
1 Year
-12.86%
-12.86%

More News

Read More
2 Recent Stock Splits You've Never Heard of That Certain Wall Street Analysts Think Could Soar 39% and 62%
Via The Motley Fool
Qiagen Earnings Review: Q4 Summary
Via Benzinga
Qiagen: Q4 Earnings Insights
Via Benzinga
Earnings Scheduled For February 5, 2025
Via Benzinga
This Workday Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
Via Benzinga
QIAGEN Strengthens Global Bioinformatics Leadership With New Data Center in Australia/Asia-Pacific Region
From QIAGEN N.V.
Via Business Wire
QIAGEN delivers solid Q4 2024 growth ahead of outlook
From QIAGEN N.V.
Via Business Wire
QIAGEN receives positive court decision reaffirming an important QuantiFERON-TB patent
From QIAGEN N.V.
Via Business Wire
QIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $300 Million
From QIAGEN N.V.
Via Business Wire
QIAGEN N.V. to Release Results for Q4 2024 and Hold Webcast
From QIAGEN N.V.
Via Business Wire
QIAGEN to Return Approximately $300 Million to Shareholders Through a Synthetic Share Repurchase
From QIAGEN N.V.
Via Business Wire
QIAGEN Increases QIAcuity Digital PCR High-Order Multiplexing Capabilities to Gain Deeper Insights From Biological Samples
From QIAGEN N.V.
Via Business Wire
QIAGEN secures U.S. clearance for first QIAstat-Dx mini gastrointestinal panel to support year-round outpatient care
From QIAGEN N.V.
Via Business Wire
QIAGEN Supports UK Initiative to Sequence Genomes of 100,000 Newborns With Expert-Curated Genomic Content
From QIAGEN N.V.
Via Business Wire
QIAGEN Launches AI-Extension of Ingenuity Pathway Analysis for Automatic Interpretation of Biological Data
From QIAGEN N.V.
Via Business Wire
QIAGEN Reaches Milestone With Over 1,000 Placements of EZ2 Connect Sample Preparation Instrument, Driving Laboratory Automation
From QIAGEN N.V.
Via Business Wire
QIAGEN Strengthens QIAstat-Dx With New Barcelona Site to Drive Growth in Infectious Diseases and Precision Medicine Testing
From QIAGEN N.V.
Via Business Wire
18 Stocks To Buy, 7 To Sell This Earnings Season: Goldman Sachs Calls It 'The Year Of The Stock Picker'
Via Benzinga
Topics Stocks
Exposures US Equities
Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12%
From Myriad Genetics, Inc.
Via GlobeNewswire
Strategic Buy Lights Up This Biotech Stock: Time to Invest?
Via MarketBeat
FDA Approves Bristol Myers Squibb's Combination Therapy For Colorectal Cancer Patients With Certain Type Of Gene Mutation
Via Benzinga
Exposures Product Safety
Vanda Pharmaceuticals And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
Qiagen Unveils Plan For $1B Shareholder Returns, Major Product Launches
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.